What is Novavax's deferred revenue, net of current portion?

Novavax (NVAX) reported deferred revenue, net of current portion of $359.27M in Q1 2026.

How has Novavax's deferred revenue, net of current portion changed year-over-year?

Novavax's deferred revenue, net of current portion decreased by 12.3% year-over-year, from $409.56M to $359.27M.

Novavax NVAX Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

ModernaMRNA

——

BioCryst PharmaceuticalsBCRX

——

Other financials

Income statement

See full

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

See full

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

See full

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

See full

Market cap$1.46B+41.0%

Enterprise value$1.53B+83.6%

P/S2.5×+1.6×

Profitability

See full

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

See full

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Novavax's deferred revenue, net of current portion?: Novavax (NVAX) reported deferred revenue, net of current portion of $359.27M in Q1 2026.
How has Novavax's deferred revenue, net of current portion changed year-over-year?: Novavax's deferred revenue, net of current portion decreased by 12.3% year-over-year, from $409.56M to $359.27M.